Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting

As the progression of low-grade diffuse astrocytomas into grade 4 tumors significantly impacts patient prognosis, a better understanding of this process is of paramount importance for improved patient care. In this project, we analyzed matched IDH-mutant astrocytomas before and after progression to...

Full description

Saved in:
Bibliographic Details
Main Authors: Rautajoki, Kirsi J. (Author) , Jaatinen, Serafiina (Author) , Hartewig, Anja (Author) , Tiihonen, Aliisa M. (Author) , Annala, Matti (Author) , Salonen, Iida (Author) , Valkonen, Masi (Author) , Simola, Vili (Author) , Vuorinen, Elisa M. (Author) , Kivinen, Anni (Author) , Rauhala, Minna J. (Author) , Nurminen, Riikka (Author) , Maaß, Kendra K. (Author) , Lahtela, Sirpa-Liisa (Author) , Jukkola, Arja (Author) , Yli-Harja, Olli (Author) , Helén, Pauli (Author) , Pajtler, Kristian Wilfried (Author) , Ruusuvuori, Pekka (Author) , Haapasalo, Joonas (Author) , Zhang, Wei (Author) , Haapasalo, Hannu (Author) , Nykter, Matti (Author)
Format: Article (Journal)
Language:English
Published: 06 November 2023
In: Acta Neuropathologica Communications
Year: 2023, Volume: 11, Pages: 1-20
ISSN:2051-5960
DOI:10.1186/s40478-023-01669-9
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s40478-023-01669-9
Get full text
Author Notes:Kirsi J. Rautajoki, Serafiina Jaatinen, Anja Hartewig, Aliisa M. Tiihonen, Matti Annala, Iida Salonen, Masi Valkonen, Vili Simola, Elisa M. Vuorinen, Anni Kivinen, Minna J. Rauhala, Riikka Nurminen, Kendra K. Maass, Sirpa-Liisa Lahtela, Arja Jukkola, Olli Yli-Harja, Pauli Helén, Kristian W. Pajtler, Pekka Ruusuvuori, Joonas Haapasalo, Wei Zhang, Hannu Haapasalo and Matti Nykter

MARC

LEADER 00000caa a2200000 c 4500
001 1889478164
003 DE-627
005 20240703181047.0
007 cr uuu---uuuuu
008 240522s2023 xx |||||o 00| ||eng c
024 7 |a 10.1186/s40478-023-01669-9  |2 doi 
035 |a (DE-627)1889478164 
035 |a (DE-599)KXP1889478164 
035 |a (OCoLC)1443676022 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Rautajoki, Kirsi J.  |e VerfasserIn  |0 (DE-588)128671642X  |0 (DE-627)1843257548  |4 aut 
245 1 0 |a Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting  |c Kirsi J. Rautajoki, Serafiina Jaatinen, Anja Hartewig, Aliisa M. Tiihonen, Matti Annala, Iida Salonen, Masi Valkonen, Vili Simola, Elisa M. Vuorinen, Anni Kivinen, Minna J. Rauhala, Riikka Nurminen, Kendra K. Maass, Sirpa-Liisa Lahtela, Arja Jukkola, Olli Yli-Harja, Pauli Helén, Kristian W. Pajtler, Pekka Ruusuvuori, Joonas Haapasalo, Wei Zhang, Hannu Haapasalo and Matti Nykter 
264 1 |c 06 November 2023 
300 |b Illustrationen 
300 |a 20 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 17.05.2024 
520 |a As the progression of low-grade diffuse astrocytomas into grade 4 tumors significantly impacts patient prognosis, a better understanding of this process is of paramount importance for improved patient care. In this project, we analyzed matched IDH-mutant astrocytomas before and after progression to grade 4 from six patients (discovery cohort) with genome-wide sequencing, 21 additional patients with targeted sequencing, and 33 patients from Glioma Longitudinal AnalySiS cohort for validation. The Cancer Genome Atlas data from 595 diffuse gliomas provided supportive information. All patients in our discovery cohort received radiation, all but one underwent chemotherapy, and no patient received temozolomide (TMZ) before progression to grade 4 disease. One case in the discovery cohort exhibited a hypermutation signature associated with the inactivation of the MSH2 and DNMT3A genes. In other patients, the number of chromosomal rearrangements and deletions increased in grade 4 tumors. The cell cycle checkpoint gene CDKN2A, or less frequently RB1, was most commonly inactivated after receiving both chemo- and radiotherapy when compared to other treatment groups. Concomitant activating PDGFRA/MET alterations were detected in tumors that acquired a homozygous CDKN2A deletion. NRG3 gene was significantly downregulated and recurrently altered in progressed tumors. Its decreased expression was associated with poorer overall survival in both univariate and multivariate analysis. We also detected progression-related alterations in RAD51B and other DNA repair pathway genes associated with the promotion of error-prone DNA repair, potentially facilitating tumor progression. In our retrospective analysis of patient treatment and survival timelines (n = 75), the combination of postoperative radiation and chemotherapy (mainly TMZ) outperformed radiation, especially in the grade 3 tumor cohort, in which it was typically given after primary surgery. Our results provide further insight into the contribution of treatment and genetic alterations in cell cycle, growth factor signaling, and DNA repair-related genes to tumor evolution and progression. 
650 4 |a Cancer genomics 
650 4 |a Diffuse glioma 
650 4 |a Homologous recombination repair 
650 4 |a Longitudinal analysis 
650 4 |a Microhomology-mediated end-joining 
650 4 |a Non-homologous end-joining 
650 4 |a RNA-sequencing 
650 4 |a Secondary glioblastoma 
700 1 |a Jaatinen, Serafiina  |e VerfasserIn  |4 aut 
700 1 |a Hartewig, Anja  |e VerfasserIn  |4 aut 
700 1 |a Tiihonen, Aliisa M.  |e VerfasserIn  |4 aut 
700 1 |a Annala, Matti  |e VerfasserIn  |4 aut 
700 1 |a Salonen, Iida  |e VerfasserIn  |4 aut 
700 1 |a Valkonen, Masi  |e VerfasserIn  |4 aut 
700 1 |a Simola, Vili  |e VerfasserIn  |4 aut 
700 1 |a Vuorinen, Elisa M.  |e VerfasserIn  |4 aut 
700 1 |a Kivinen, Anni  |e VerfasserIn  |4 aut 
700 1 |a Rauhala, Minna J.  |e VerfasserIn  |4 aut 
700 1 |a Nurminen, Riikka  |e VerfasserIn  |4 aut 
700 1 |a Maaß, Kendra K.  |e VerfasserIn  |0 (DE-588)117149629X  |0 (DE-627)104056514X  |0 (DE-576)513763988  |4 aut 
700 1 |a Lahtela, Sirpa-Liisa  |e VerfasserIn  |4 aut 
700 1 |a Jukkola, Arja  |e VerfasserIn  |4 aut 
700 1 |a Yli-Harja, Olli  |e VerfasserIn  |4 aut 
700 1 |a Helén, Pauli  |e VerfasserIn  |4 aut 
700 1 |a Pajtler, Kristian Wilfried  |d 1980-  |e VerfasserIn  |0 (DE-588)1012877264  |0 (DE-627)662768558  |0 (DE-576)346086256  |4 aut 
700 1 |a Ruusuvuori, Pekka  |e VerfasserIn  |4 aut 
700 1 |a Haapasalo, Joonas  |e VerfasserIn  |4 aut 
700 1 |a Zhang, Wei  |e VerfasserIn  |4 aut 
700 1 |a Haapasalo, Hannu  |e VerfasserIn  |4 aut 
700 1 |a Nykter, Matti  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Acta Neuropathologica Communications  |d London : Biomed Central, 2013  |g 11(2023), Artikel-ID 176, Seite 1-20  |h Online-Ressource  |w (DE-627)746066465  |w (DE-600)2715589-4  |w (DE-576)382284372  |x 2051-5960  |7 nnas  |a Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting 
773 1 8 |g volume:11  |g year:2023  |g elocationid:176  |g pages:1-20  |g extent:20  |a Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting 
856 4 0 |u https://doi.org/10.1186/s40478-023-01669-9  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240522 
993 |a Article 
994 |a 2023 
998 |g 1012877264  |a Pajtler, Kristian Wilfried  |m 1012877264:Pajtler, Kristian Wilfried  |d 910000  |d 910500  |d 50000  |e 910000PP1012877264  |e 910500PP1012877264  |e 50000PP1012877264  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 18 
998 |g 117149629X  |a Maaß, Kendra K.  |m 117149629X:Maaß, Kendra K.  |d 910000  |d 910500  |d 50000  |e 910000PM117149629X  |e 910500PM117149629X  |e 50000PM117149629X  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 13 
999 |a KXP-PPN1889478164  |e 4527024655 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"06 November 2023"}],"id":{"eki":["1889478164"],"doi":["10.1186/s40478-023-01669-9"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"746066465","language":["eng"],"note":["Gesehen am 29.11.18"],"id":{"eki":["746066465"],"issn":["2051-5960"],"zdb":["2715589-4"]},"part":{"year":"2023","extent":"20","text":"11(2023), Artikel-ID 176, Seite 1-20","volume":"11","pages":"1-20"},"origin":[{"dateIssuedKey":"2013","publisherPlace":"London","publisher":"Biomed Central","dateIssuedDisp":"2013-"}],"title":[{"title_sort":"Acta Neuropathologica Communications","title":"Acta Neuropathologica Communications"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2013 -"],"disp":"Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment settingActa Neuropathologica Communications"}],"recId":"1889478164","language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"20 S."}],"person":[{"given":"Kirsi J.","family":"Rautajoki","display":"Rautajoki, Kirsi J.","role":"aut","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Jaatinen, Serafiina","family":"Jaatinen","given":"Serafiina"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hartewig, Anja","family":"Hartewig","given":"Anja"},{"family":"Tiihonen","given":"Aliisa M.","display":"Tiihonen, Aliisa M.","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Annala, Matti","roleDisplay":"VerfasserIn","role":"aut","given":"Matti","family":"Annala"},{"family":"Salonen","given":"Iida","role":"aut","roleDisplay":"VerfasserIn","display":"Salonen, Iida"},{"given":"Masi","family":"Valkonen","role":"aut","roleDisplay":"VerfasserIn","display":"Valkonen, Masi"},{"given":"Vili","family":"Simola","display":"Simola, Vili","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Vuorinen, Elisa M.","role":"aut","roleDisplay":"VerfasserIn","given":"Elisa M.","family":"Vuorinen"},{"family":"Kivinen","given":"Anni","roleDisplay":"VerfasserIn","role":"aut","display":"Kivinen, Anni"},{"family":"Rauhala","given":"Minna J.","display":"Rauhala, Minna J.","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Nurminen","given":"Riikka","display":"Nurminen, Riikka","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Maaß, Kendra K.","role":"aut","roleDisplay":"VerfasserIn","given":"Kendra K.","family":"Maaß"},{"display":"Lahtela, Sirpa-Liisa","roleDisplay":"VerfasserIn","role":"aut","family":"Lahtela","given":"Sirpa-Liisa"},{"given":"Arja","family":"Jukkola","role":"aut","roleDisplay":"VerfasserIn","display":"Jukkola, Arja"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Yli-Harja, Olli","given":"Olli","family":"Yli-Harja"},{"family":"Helén","given":"Pauli","display":"Helén, Pauli","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Kristian Wilfried","family":"Pajtler","role":"aut","roleDisplay":"VerfasserIn","display":"Pajtler, Kristian Wilfried"},{"display":"Ruusuvuori, Pekka","roleDisplay":"VerfasserIn","role":"aut","family":"Ruusuvuori","given":"Pekka"},{"display":"Haapasalo, Joonas","roleDisplay":"VerfasserIn","role":"aut","given":"Joonas","family":"Haapasalo"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Zhang, Wei","given":"Wei","family":"Zhang"},{"given":"Hannu","family":"Haapasalo","display":"Haapasalo, Hannu","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Nykter, Matti","given":"Matti","family":"Nykter"}],"note":["Gesehen am 17.05.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting","title":"Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting"}],"name":{"displayForm":["Kirsi J. Rautajoki, Serafiina Jaatinen, Anja Hartewig, Aliisa M. Tiihonen, Matti Annala, Iida Salonen, Masi Valkonen, Vili Simola, Elisa M. Vuorinen, Anni Kivinen, Minna J. Rauhala, Riikka Nurminen, Kendra K. Maass, Sirpa-Liisa Lahtela, Arja Jukkola, Olli Yli-Harja, Pauli Helén, Kristian W. Pajtler, Pekka Ruusuvuori, Joonas Haapasalo, Wei Zhang, Hannu Haapasalo and Matti Nykter"]}} 
SRT |a RAUTAJOKIKGENOMICCHA0620